
HCA Healthcare (HCA) Stock Forecast & Price Target
HCA Healthcare (HCA) Analyst Ratings
Bulls say
HCA Healthcare has demonstrated notable financial growth, highlighted by a 9.2% increase in same-facility revenues and a 7.1% rise in inpatient revenue per admission year-over-year during the third quarter of 2025. Additionally, the organization's strong payer mix has enabled significant revenue growth across various segments, with Medicare and commercial admissions seeing year-over-year increases of 3.4% and 3.7%, respectively. Furthermore, HCA raised its 2025 adjusted EBITDA guidance to a range of $15.25 billion to $15.65 billion, reflecting core operational strength and a positive shift in the revenue outlook.
Bears say
HCA Healthcare's total debt to last twelve months (LTM) EBITDA ratio decreased slightly to 2.9x in the third quarter of 2025, indicating a potential concern regarding future earnings growth amidst a forecasted headwind for 2026. Additionally, the company has revised its estimated EBITDA growth down to 3.9%, which falls below the low end of its long-term growth outlook, suggesting weakening operational performance. The adjustment of HCA's leverage target to a narrower range of 2.75x-3.75x further highlights increasing caution about the company's financial stability in the changing economic environment.
This aggregate rating is based on analysts' research of HCA Healthcare and is not a guaranteed prediction by Public.com or investment advice.
HCA Healthcare (HCA) Analyst Forecast & Price Prediction
Start investing in HCA Healthcare (HCA)
Order type
Buy in
Order amount
Est. shares
0 shares